If you've had a total hysterectomy, meaning your entire uterus, including the cervix, was removed, you generally do not need to take progesterone or a progestin alongside estrogen therapy.

The only job progestogen has in a hormone therapy regimen is protecting the endometrium (the uterine lining) from the hyperplasia, and rare cancer risk, that unopposed estrogen exposure can cause; without a uterus, there is no endometrium left to protect, so The Menopause Society's 2022 position statement and earlier clinical reviews support estrogen-only therapy for this group. A few situations complicate the picture. If your surgery was a supracervical (partial, or "subtotal") hysterectomy, your cervix, and possibly a strip of endometrial-type tissue near it, remains in place, and some clinicians extend progestogen coverage for that reason, though this specific scenario hasn't been directly studied in trials. If you have a history of endometriosis, especially if some disease may have been left behind at surgery, some gynecologists add a progestogen anyway, reasoning that residual, estrogen-responsive endometriosis tissue outside the uterus could still respond to unopposed estrogen; the evidence for this practice is observational, reassuring but limited, not settled. Low-dose vaginal estrogen used for local symptoms like dryness is a separate case: because so little reaches the bloodstream, it is not thought to need progestogen protection at all, whether or not a uterus is present. This is ultimately a decision to make with your own doctor, based on exactly what was, and wasn't, removed at surgery.

What to know about this answer

For most women who no longer have a uterus, the progestogen question is one of the more settled corners of hormone therapy: estrogen alone is standard, and the major guideline bodies agree. The real tension shows up only in the minority of cases where a woman also has a history of endometriosis. Because endometriosis tissue is itself estrogen-responsive and can persist outside the uterus even after a technically total hysterectomy, some specialists still recommend adding a progestogen, arguing it may lower the already-low risk of symptom recurrence or, in rare cases, malignant change in residual disease. Others hold that the actual evidence for this added benefit is thin, retrospective, and confounded by how completely the disease was excised at surgery, and that adding a progestogen simply reintroduces the same breast-cancer trade-off seen in combined regimens generally.

What the research shows, and which source each finding rests on

Progestogen's sole role in a hormone therapy regimen that includes estrogen is to protect the endometrium against the hyperplasia and cancer risk of unopposed estrogen exposure; women with no uterus after total hysterectomy have no endometrium to protect, so The Menopause Society's 2022 position statement supports estrogen-only therapy as the standard approach for this group, with treatment individualized to risks and benefits.

A[1]

A clinical review focused specifically on hormone therapy after hysterectomy concludes that for most women without a uterus, current literature favors not adding a progestogen: combined estrogen-progestogen regimens are associated with a greater relative risk of breast cancer than estrogen alone, without added relief of hot flashes or vaginal symptoms, and may attenuate estrogen's cardiovascular benefit without improving bone protection.

?[2]

In a retrospective cohort of 123 women who had undergone hysterectomy with bilateral oophorectomy for endometriosis, the estrogen-only group (n=50) had a 2% rate of recurrent endometriosis and a 6% rate of recurrent symptoms, and the study authors reported recurrence was rarer still among women on cyclic or continuous combined estrogen-progestin regimens, with no cases of malignant transformation observed in any group, suggesting hormone therapy is broadly safe after surgical menopause even with an endometriosis history, though the small per-group sample sizes cannot rule out rare events.

?[3]

A systematic evidence review of 20 randomized controlled trials and multiple observational studies (nearly 3,000 women across the RCTs) found that low-dose vaginal estrogen used without a progestogen was not associated with an increased rate of endometrial hyperplasia (0.4% pooled) or endometrial cancer (0.03% pooled), rates consistent with baseline rates in the general postmenopausal population, supporting its use without progestogen regardless of whether the uterus is present.

?[4]

Where the real disagreement is

Each position is shown with its own sources. A position listed here is not necessarily the accepted view.

Estrogen-only is the standard, full stop

The Menopause Society and most gynecologists following the 2022 position statement and prior hysterectomy-specific reviews

The endometrium is the only tissue progestogen protects, and once it is gone after a total hysterectomy, there is nothing left to protect. Adding a progestogen back in mainly adds the breast-cancer signal seen with combined regimens, without a clear offsetting benefit for most women.

A[1]?[2]

Some clinicians add it back for a history of endometriosis

gynecologists specializing in endometriosis management, per reviews such as Alio et al. 2019

Endometriosis is, by definition, estrogen-responsive tissue growing outside the uterus. Hysterectomy alone doesn't guarantee every implant was removed, and case literature has described rare malignant transformation of residual endometriosis under strong estrogenic stimulation. Some clinicians extrapolate from this that adding a progestogen may offer a margin of safety, even though the practice has not been tested in a controlled trial.

?[5]?[3]

What would settle it: A prospective, adequately powered trial randomizing post-hysterectomy women with a documented history of endometriosis, ideally with a record of how completely the disease was excised, to estrogen-only versus combined estrogen-progestogen therapy, with long enough follow-up to compare rates of symptom recurrence and the very rare outcome of malignant transformation.

What is really going on here

  1. Was my hysterectomy total, including the cervix, or supracervical, leaving the cervix in place?
  2. If I had endometriosis, how confident is my surgeon that all visible disease was removed at the time of hysterectomy?
  3. Is the estrogen I'm being offered a systemic dose (pill, patch, gel) or a low-dose vaginal product, since that changes whether unopposed use is even a meaningful concern?

Questions for your doctor

  1. Did my hysterectomy remove my cervix, or just the uterus above it?
  2. Given my surgical history, do you recommend estrogen alone or an estrogen-progestogen combination for me?
  3. If I had endometriosis, is there tissue that might still be estrogen-responsive, and does that change your recommendation?
  4. If I'm only using vaginal estrogen for dryness or discomfort, do I need any progestogen for that?

Questions with no answer yet

Does a supracervical (subtotal) hysterectomy, which leaves the cervix and possibly a strip of endometrial-type tissue in place, change the recommendation on progestogen?

Not directly studied yet

No research does not mean it does not work, and it does not mean it works. It means nobody has tested it yet.

What is known: General hormone therapy reviews address total hysterectomy specifically. No identified trial or guideline directly studies progestogen need in the supracervical hysterectomy subgroup. Clinically, some clinicians extend progestogen coverage anyway because a strip of endometrial-type tissue can persist near the cervix or lower uterine segment after this procedure.

What would test it: A cohort study tracking endometrial-type tissue persistence (via imaging or biopsy where feasible) and rates of abnormal bleeding or malignancy in women who had a supracervical hysterectomy, comparing estrogen-only versus combined therapy.

Does adding a progestogen after hysterectomy actually lower the rate of malignant transformation in residual endometriosis, or is that only a theoretical rationale?

Not directly studied yet

No research does not mean it does not work, and it does not mean it works. It means nobody has tested it yet.

What is known: Malignant transformation of endometriosis is itself rare, and the cases described in the literature are individual case reports, not controlled comparisons of estrogen-only versus combined therapy in this specific population.

What would test it: Long-term registry data or a randomized trial comparing regimens in women with a documented endometriosis history, adequately powered for this rare outcome, which would likely require multi-decade, multi-center follow-up given how infrequently it occurs.

Sources

  1. 1.The 2022 hormone therapy position statement of The North American Menopause Society.The 2022 Hormone Therapy Position Statement of The North American Menopause Society, Menopause 2022 · Systematic review or guideline
  2. 2.Haney AF, Wild RA, Menopause 2007Not rated
  3. 3.Rattanachaiyanont M et al., J Med Assoc Thai 2003Not rated
  4. 4.Constantine GD et al., Menopause 2019Not rated
  5. 5.Alio L et al., Climacteric 2019Not rated

The letter grades the type of study behind a claim, not the answer itself.

This page is general information based on published research and public sources. It is not medical advice and not a personal assessment, and it does not replace a conversation with your doctor. Peritale is a wellness product, not a medical device, and is not intended to diagnose, treat, cure or prevent any disease. For any medical question, speak with a licensed clinician.

You are not imagining it

In about seven minutes on your phone, Peritale reads five signal systems and maps your symptoms, so you can see that what you feel is real, follow your hormonal transition over time, and walk into your doctor ready to ask for the care you deserve. Your first check is free, no credit card.

Start Free Mapping

Related questions

Related guides